As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated Intrinsic Value is $354.5. This suggests it may be overvalued by 13.5% compared to its current price of around $409.9.
As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at $499.0. This suggests it may be overvalued by 21.7% to its current price of around $409.9, using a discount rate of 7.9% and terminal growth rate of 3.0%.
Vertex Pharmaceuticals Incorporated is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $354.5, compared to a market price of around $409.9. This suggests a potential overvaluation of 13.5%.